Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


UCL Enterprise – your views

25 January 2013

UCL Enterprise

Stephen Caddick, Vice-Provost (Enterprise), and his colleagues would like to hear your views on UCL Enterprise – its mission, its relevance and your experience and involvement.

The survey is very short and will only take a few minutes to complete and so I urge you to take the time to answer even if you have not yet had much involvement with enterprise or knowledge exchange - this is your chance to have your say and getting a UCL-wide picture will be invaluable in informing the future strategy and direction of UCL Enterprise.

The survey can be accessed here